vs

Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $16.9M, roughly 1.2× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -8.7%). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -0.5%).

FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

FVCB vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.2× larger
LUNG
$20.6M
$16.9M
FVCB
Growing faster (revenue YoY)
FVCB
FVCB
+4386.2% gap
FVCB
4377.5%
-8.7%
LUNG
Faster 2-yr revenue CAGR
FVCB
FVCB
Annualised
FVCB
586.6%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FVCB
FVCB
LUNG
LUNG
Revenue
$16.9M
$20.6M
Net Profit
$-13.7M
Gross Margin
77.9%
Operating Margin
43.7%
-40.9%
Net Margin
-66.3%
Revenue YoY
4377.5%
-8.7%
Net Profit YoY
5.5%
EPS (diluted)
$0.31
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FVCB
FVCB
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$16.9M
$22.6M
Q3 25
$416.0K
$21.5M
Q2 25
$15.8M
$23.9M
Q1 25
$382.0K
$22.5M
Q4 24
$378.0K
$23.8M
Q3 24
$412.0K
$20.4M
Q2 24
$415.0K
$20.8M
Net Profit
FVCB
FVCB
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$5.6M
$-14.0M
Q2 25
$5.7M
$-15.2M
Q1 25
$5.2M
$-14.4M
Q4 24
$-13.2M
Q3 24
$4.7M
$-14.1M
Q2 24
$4.2M
$-15.3M
Gross Margin
FVCB
FVCB
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
FVCB
FVCB
LUNG
LUNG
Q1 26
-40.9%
Q4 25
43.7%
-43.8%
Q3 25
-66.9%
Q2 25
45.9%
-62.0%
Q1 25
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
Q2 24
-75.2%
Net Margin
FVCB
FVCB
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
1341.1%
-64.9%
Q2 25
36.0%
-63.6%
Q1 25
1352.1%
-64.1%
Q4 24
-55.4%
Q3 24
1133.3%
-69.4%
Q2 24
1001.2%
-73.7%
EPS (diluted)
FVCB
FVCB
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$0.31
$-0.25
Q3 25
$0.31
$-0.34
Q2 25
$0.31
$-0.38
Q1 25
$0.28
$-0.36
Q4 24
$0.27
$-0.33
Q3 24
$0.25
$-0.36
Q2 24
$0.23
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FVCB
FVCB
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$253.6M
$45.8M
Total Assets
$2.3B
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FVCB
FVCB
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
FVCB
FVCB
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
FVCB
FVCB
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$253.6M
$54.1M
Q3 25
$249.8M
$60.0M
Q2 25
$243.2M
$69.1M
Q1 25
$242.3M
$77.7M
Q4 24
$235.4M
$85.8M
Q3 24
$230.8M
$93.9M
Q2 24
$226.5M
$101.2M
Total Assets
FVCB
FVCB
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$2.3B
$129.3M
Q3 25
$2.3B
$138.3M
Q2 25
$2.2B
$147.2M
Q1 25
$2.2B
$150.7M
Q4 24
$2.2B
$162.8M
Q3 24
$2.3B
$167.4M
Q2 24
$2.3B
$172.6M
Debt / Equity
FVCB
FVCB
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FVCB
FVCB
LUNG
LUNG
Operating Cash FlowLast quarter
$23.9M
Free Cash FlowOCF − Capex
$23.8M
FCF MarginFCF / Revenue
140.7%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$40.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FVCB
FVCB
LUNG
LUNG
Q1 26
Q4 25
$23.9M
$-7.1M
Q3 25
$7.6M
$-8.2M
Q2 25
$3.3M
$-3.9M
Q1 25
$5.4M
$-13.2M
Q4 24
$18.2M
$-6.7M
Q3 24
$4.7M
$-7.2M
Q2 24
$1.6M
$-5.8M
Free Cash Flow
FVCB
FVCB
LUNG
LUNG
Q1 26
Q4 25
$23.8M
$-7.1M
Q3 25
$7.6M
$-8.3M
Q2 25
$3.3M
$-4.0M
Q1 25
$5.4M
$-13.5M
Q4 24
$18.1M
$-6.8M
Q3 24
$4.6M
$-7.7M
Q2 24
$1.5M
$-6.2M
FCF Margin
FVCB
FVCB
LUNG
LUNG
Q1 26
Q4 25
140.7%
-31.4%
Q3 25
1818.0%
-38.4%
Q2 25
20.8%
-16.6%
Q1 25
1413.6%
-60.0%
Q4 24
4786.0%
-28.8%
Q3 24
1121.8%
-37.6%
Q2 24
361.2%
-30.0%
Capex Intensity
FVCB
FVCB
LUNG
LUNG
Q1 26
Q4 25
0.3%
0.1%
Q3 25
0.2%
0.4%
Q2 25
0.1%
0.2%
Q1 25
4.2%
1.3%
Q4 24
37.3%
0.5%
Q3 24
14.1%
2.0%
Q2 24
12.8%
2.3%
Cash Conversion
FVCB
FVCB
LUNG
LUNG
Q1 26
Q4 25
Q3 25
1.36×
Q2 25
0.58×
Q1 25
1.05×
Q4 24
Q3 24
1.00×
Q2 24
0.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons